NAPROXEN SODIUM CAPLETS TABLET
Ülke: Kanada
Dil: İngilizce
Kaynak: Health Canada
Ürün özellikleri
(SPC)
31-01-2012
Bu ürün için bazı belgeler şu anda mevcut değil, müşteri hizmetlerimize bir istek gönderebilirsiniz ve bunları alır almaz size bildireceğiz.
İstek gönder.
İstek gönder.
Aktif bileşen:
NAPROXEN SODIUM
Mevcut itibaren:
VITA HEALTH PRODUCTS INC
ATC kodu:
M01AE02
INN (International Adı):
NAPROXEN
Doz:
220MG
Farmasötik formu:
TABLET
Kompozisyon:
NAPROXEN SODIUM 220MG
Uygulama yolu:
ORAL
Paketteki üniteler:
100
Reçete türü:
OTC
Terapötik alanı:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Ürün özeti:
Active ingredient group (AIG) number: 0113934003; AHFS:
Yetkilendirme durumu:
APPROVED
Yetkilendirme tarihi:
2012-01-30
Ürün özellikleri
_Page 1 of 35_
PRODUCT MONOGRAPH
NAPROXEN SODIUM TABLETS
NAPROXEN SODIUM CAPLETS
NAPROXEN SODIUM TABLETS USP, 220 MG
Non-steroidal anti-inflammatory drug
Analgesic, Antipyretic
Vita Health Products Inc.
150 Beghin Avenue, Winnipeg
Manitoba, Canada R2J 3W2
Date of Preparation:
January 26, 2012
Control No.: 134246
_Page 2 of 35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.............................................................................3
SUMMARY PRODUCT INFORMATION
.............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................................
6
DRUG INTERACTIONS
.........................................................................................................................
9
DOSAGE AND ADMINISTRATION
...................................................................................................11
OVERDOSAGE
.....................................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................12
STORAGE AND STABILITY
...............................................................................................................13
SPECIAL HANDLING INSTRUCTIONS
............................................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................................14
PART II:
Belgenin tamamını okuyun
